Benign Cardiac Tumors
- Author: Dale K Mueller, MD; Chief Editor: Karlheinz Peter, MD, PhD more...
In general, primary tumors of the heart are rare. In autopsy studies, the overall prevalence ranges from 0.002-0.25%.
Although most tumors of the heart are benign, because of their malignant potential, the risks secondary to impaired cardiac function (eg, congestive heart failure, inflow/outflow tract obstruction), conduction system involvement, and/or peripheral embolism mandate prompt evaluation and definitive treatment.
It has been reported that patients with benign cardiac tumors are at increased risk of first ischemic stroke, particularly patients younger than 50 years.
The most common primary cardiac tumor is a myxoma. Other less common neoplastic tissue types occur; each has distinguishing characteristics that often aid in accurate preoperative diagnosis or diagnosis prior to death. A definitive diagnosis is important because some cardiac tumors can be malignant or, more commonly, can represent metastasis from a distant primary tumor.
Myxomas arise usually from the endocardium and range in size from 1-20 cm. The vast majority (86%) develop from the left atrium, with the remainder developing from the right atrium. They tend to develop from the fossa ovalis but can be found arising from anywhere in the atrium. Ventricular or valvular sites are rare.
Rhabdomyomas are intramural tumors that are typically smaller and most often involve the left (80%) or right (15%) ventricles.
Fibromas most commonly involve the intraventricular septum or left ventricular free wall. Less than 10% of reported cases have atrial or great vessel involvement. Unlike myxomas, tumor embolization is uncommon. Tumor growth can displace or directly involve mitral and aortic valves and result in hemodynamically significant valvular stenosis or regurgitation.
Symptoms are typically secondary to adverse effects on normal left ventricular geometry, filling, and ejection. Additionally, arrhythmias, particularly sudden death and abnormal atrioventricular conduction, are common because of tumor disruption of the nodal or septal conduction tissue. Benign cardiac tumors can also present without symptoms as incidental findings found on cardiac studies investigating other pathology.
Benign cardiac tumors are extremely rare. Of all primary cardiac tumors, 75% are histologically benign. Myxomas represent approximately 75% of benign tumors, while rhabdomyomas (5-10%) and fibromas (4-6%) occur less commonly.
The prognosis is excellent, including disease-free survival, if the tumor is completely resected. Incomplete resections predispose patients to further tumor growth and recurrence of symptoms; risk is undefined.
Although unproved, concern for recurrence, similar to that for fibromas found in other parts of the body, is warranted.
Systemic embolization is the most common causes of complications. It is typically a presenting symptom in 25-50% of cases. Embolization can occur to any end organ including the brain, lower extremities, kidneys, and heart (coronary artery) with subsequent ischemia and possible infarction. Cardiac tumor should be in the differential diagnosis when evaluating any cause of embolization. Rhabdomyomas often manifest early in life with inflow/outflow obstruction (ie, heart failure) or arrhythmia and resection is typically indicated.
Despite complete resection, patients are still at risk for sudden death due to damage to the conduction system.
The role of prophylactic antiarrhythmics or implanted cardioverter/defibrillators is undefined.
No known sex predilection is recognized, although the rarity of the different benign cardiac tumors prevents accurate determination of a male-to-female ratio.
Myxomas are the most common tumors in adults. However, rhabdomyoma is the most common tumor in children (second most common benign cardiac tumor overall). Fibromas are rare and typically occur in children.
Lai MM, Li TC, Lin CL, Sung FC, Lin CC, Liu CS, et al. Benign neoplasm of the heart increases the risk of first ischemic stroke: a population-based cohort study. Int J Stroke. 2014 Jul 23. [Medline].
Salcedo EE, Cohen GI, White RD, Davison MB. Cardiac tumors: diagnosis and management. Curr Probl Cardiol. 1992 Feb. 17(2):73-137. [Medline].
Lund JT, Ehman RL, Julsrud PR, et al. Cardiac masses: assessment by MR imaging. AJR Am J Roentgenol. 1989 Mar. 152(3):469-73. [Medline].
Pazos-Lopez P, Pozo E, Siqueira ME, et al. Value of CMR for the differential diagnosis of cardiac masses. JACC Cardiovasc Imaging. 2014 Sep. 7(9):896-905. [Medline].
Centofanti P, DiRose E, Deorsola L, et al. Primary cardiac tumors: early and late results of surgical treatment in 91 patients. Ann Thorac Surg. 1999. 68(4):1236-41. [Medline].
Reardon MJ, Malaisrie SC, Walkes JC, et al. Cardiac autotransplantation for primary cardiac tumors. Ann Thorac Surg. 2006 Aug. 82(2):645-50. [Medline].
Padalino MA, Basso C, Milanesi O. Surgically treated primary cardiac tumors in early infancy and childhood. J Thorac Cardiovasc Surg. 2005 Jun. 129(6):1358-63. [Medline].
Michler RE, Goldstein DJ. Treatment of cardiac tumors by orthotopic cardiac transplantation. Semin Oncol. 1997. 24(5):534-9. [Medline].
Williams DB, Danielson GK, McGoon DC, et al. Cardiac fibroma: long-term survival after excision. J Thorac Cardiovasc Surg. 1982 Aug. 84(2):230-6. [Medline].